Assessment of a Noninvasive Exhaled Breath Test for the Diagnosis of Oesophagogastric Cancer

Sheraz R Markar, Tom Wiggins, Stefan Antonowicz, Sung-Tong Chin, Andrea Romano, Konstantin Nikolic, Benjamin Evans, David Cunningham, Muntzer Mughal, Jesper Lagergren, George B Hanna, Sheraz R Markar, Tom Wiggins, Stefan Antonowicz, Sung-Tong Chin, Andrea Romano, Konstantin Nikolic, Benjamin Evans, David Cunningham, Muntzer Mughal, Jesper Lagergren, George B Hanna

Abstract

Importance: Early esophagogastric cancer (OGC) stage presents with nonspecific symptoms.

Objective: The aim of this study was to determine the accuracy of a breath test for the diagnosis of OGC in a multicenter validation study.

Design, setting, and participants: Patient recruitment for this diagnostic validation study was conducted at 3 London hospital sites, with breath samples returned to a central laboratory for selected ion flow tube mass spectrometry (SIFT-MS) analysis. Based on a 1:1 cancer:control ratio, and maintaining a sensitivity and specificity of 80%, the sample size required was 325 patients. All patients with cancer were on a curative treatment pathway, and patients were recruited consecutively. Among the 335 patients included; 172 were in the control group and 163 had OGC.

Interventions: Breath samples were collected using secure 500-mL steel breath bags and analyzed by SIFT-MS. Quality assurance measures included sampling room air, training all researchers in breath sampling, regular instrument calibration, and unambiguous volatile organic compounds (VOCs) identification by gas chromatography mass spectrometry.

Main outcomes and measures: The risk of cancer was identified based on a previously generated 5-VOCs model and compared with histopathology-proven diagnosis.

Results: Patients in the OGC group were older (median [IQR] age 68 [60-75] vs 55 [41-69] years) and had a greater proportion of men (134 [82.2%]) vs women (81 [47.4%]) compared with the control group. Of the 163 patients with OGC, 123 (69%) had tumor stage T3/4, and 106 (65%) had nodal metastasis on clinical staging. The predictive probabilities generated by this 5-VOCs diagnostic model were used to generate a receiver operator characteristic curve, with good diagnostic accuracy, area under the curve of 0.85. This translated to a sensitivity of 80% and specificity of 81% for the diagnosis of OGC.

Conclusions and relevance: This study shows the potential of breath analysis in noninvasive diagnosis of OGC in the clinical setting. The next step is to establish the diagnostic accuracy of the test among the intended population in primary care where the test will be applied.

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure.. ROC Curve for the 5-VOC Breath…
Figure.. ROC Curve for the 5-VOC Breath Model in the Diagnosis of Esophagogastric Cancer in the Multicenter Clinical Triala
Abbreviations: ROC, receiver operating characteristic curve; VOC, volatile organic compounds. aArea under the curve of 0.85 (SD, 0.02).

References

    1. Bodger K, Eastwood PG, Manning SI, Daly MJ, Heatley RV. Dyspepsia workload in urban general practice and implications of the British Society of Gastroenterology Dyspepsia guidelines (1996). Aliment Pharmacol Ther. 2000;14(4):413-420.
    1. National Oesophago-Gastric Cancer Audit 2016. . Accessed September 11, 2016.
    1. National Initiative for Health and Care Excellence NICE guidelines for suspected cancer. 2015; (June). .
    1. Shawihdi M, Thompson E, Kapoor N, et al. . Variation in gastroscopy rate in English general practice and outcome for oesophagogastric cancer: retrospective analysis of Hospital Episode Statistics. Gut. 2014;63(2):250-261.
    1. Markar SR, Mackenzie H, Jemal S, et al. . Emergency presentation of esophagogastric cancer: predictors and long-term prognosis. Ann Surg. 2017;267(4):711-715.
    1. Pauling L, Robinson AB, Teranishi R, Cary P. Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc Natl Acad Sci U S A. 1971;68(10):2374-2376.
    1. Spanel P, Smith D, Holland TA, Al Singary W, Elder JB. Analysis of formaldehyde in the headspace of urine from bladder and prostate cancer patients using selected ion flow tube mass spectrometry. Rapid Commun Mass Spectrom. 1999;13(14):1354-1359.
    1. Silva CL, Passos M, Câmara JS. Investigation of urinary volatile organic metabolites as potential cancer biomarkers by solid-phase microextraction in combination with gas chromatography-mass spectrometry. Br J Cancer. 2011;105(12):1894-1904.
    1. Phillips M, Gleeson K, Hughes JM, et al. . Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet. 1999;353(9168):1930-1933.
    1. Kumar S, Huang J, Abbassi-Ghadi N, et al. . Mass spectrometric analysis of exhaled breath for the identification of volatile organic compound biomarkers in esophageal and gastric adenocarcinoma. Ann Surg. 2015;262(6):981-990.
    1. Kumar S, Huang J, Abbassi-Ghadi N, Španěl P, Smith D, Hanna GB. Selected ion flow tube mass spectrometry analysis of exhaled breath for volatile organic compound profiling of esophago-gastric cancer. Anal Chem. 2013;85(12):6121-6128.
    1. Altomare DF, Di Lena M, Porcelli F, et al. . Exhaled volatile organic compounds identify patients with colorectal cancer. Br J Surg. 2013;100(1):144-150.
    1. Peng G, Hakim M, Broza YY, et al. . Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. Br J Cancer. 2010;103(4):542-551.
    1. Markar SR, Lagergren J, Hanna GB. Research protocol for a diagnostic study of non-invasive exhaled breath analysis for the prediction of oesophago-gastric cancer. BMJ Open. 2016;6(1):e009139.
    1. Bossuyt PM, Reitsma JB, Bruns DE, et al. ; STARD Group . STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527.
    1. Boshier PR, Priest OH, Hanna GB, Marczin N. Influence of respiratory variables on the on-line detection of exhaled trace gases by PTR-MS. Thorax. 2011;66(10):919-920.
    1. Boshier PR, Cushnir JR, Priest OH, Marczin N, Hanna GB. Variation in the levels of volatile trace gases within three hospital environments: implications for clinical breath testing. J Breath Res. 2010;4(3):031001.
    1. Spanĕl P, Smith D. Selected ion flow tube mass spectrometry for on-line trace gas analysis in biology and medicine. Eur J Mass Spectrom (Chichester). 2007;13(1):77-82.
    1. Spaněl P, Smith D. Progress in SIFT-MS: breath analysis and other applications. Mass Spectrom Rev. 2011;30(2):236-267.
    1. Spanel P, Smith D, Holland TA, et al. . Analysis of formaldehyde in the headspace of urine from bladder and prostate cancer patients using selected ion flow tube mass spectrometry. Rapid Commun Mass Spectrom. 1999;13(14):1354-1359.
    1. Smith D, Sovová K, Dryahina K, Doušová T, Dřevínek P, Španěl P. Breath concentration of acetic acid vapour is elevated in patients with cystic fibrosis. J Breath Res. 2016;10(2):021002.
    1. Boshier PR, Cushnir JR, Mistry V, et al. . On-line, real time monitoring of exhaled trace gases by SIFT-MS in the perioperative setting: a feasibility study. Analyst. 2011;136(16):3233-3237.
    1. Boshier PR, Marczin N, Hanna GB. Repeatability of the measurement of exhaled volatile metabolites using selected ion flow tube mass spectrometry. J Am Soc Mass Spectrom. 2010;21(6):1070-1074.
    1. Rosman AS, Korsten MA. Effect of verification bias on the sensitivity of fecal occult blood testing: a meta-analysis. J Gen Intern Med. 2010;25(11):1211-1221.
    1. Kadri SR, Lao-Sirieix P, O’Donovan M, et al. . Acceptability and accuracy of a non-endoscopic screening test for Barrett’s oesophagus in primary care: cohort study. BMJ. 2010;341:c4372.
    1. Markar SR, Chin ST, Romano A, et al. . Breath volatile organic compound profiling of colorectal cancer using selected ion flow-tube mass spectrometry [published online November 29, 2017]. Ann Surg. doi:10.1097/SLA.0000000000002539
    1. Kang S, Paul Thomas CL. How long may a breath sample be stored for at -80 °C? A study of the stability of volatile organic compounds trapped onto a mixed Tenax:Carbograph trap adsorbent bed from exhaled breath. J Breath Res. 2016;10(2):026011.
    1. Doran SLF, Romano A, Hanna GB. Optimisation of sampling parameters for standardised exhaled breath sampling. J Breath Res. 2017;12(1):016007.
    1. Fang P, Jiao S, Zhang X, et al. . Meta-analysis of ALDH2 variants and esophageal cancer in Asians. Asian Pac J Cancer Prev. 2011;12(10):2623-2627.
    1. Abbassi-Ghadi N, Kumar S, Huang J, Goldin R, Takats Z, Hanna GB. Metabolomic profiling of oesophago-gastric cancer: a systematic review. Eur J Cancer. 2013;49(17):3625-3637.
    1. Kokoszka J, Nelson RL, Swedler WI, Skosey J, Abcarian H. Determination of inflammatory bowel disease activity by breath pentane analysis. Dis Colon Rectum. 1993;36(6):597-601.
    1. Wroblewski LE, Peek RM Jr, Coburn LA. The role of the microbiome in gastrointestinal cancer. Gastroenterol Clin North Am. 2016;45(3):543-556.
    1. Thorn RM, Reynolds DM, Greenman J. Multivariate analysis of bacterial volatile compound profiles for discrimination between selected species and strains in vitro. J Microbiol Methods. 2011;84(2):258-264.
    1. Chadwick G, Groene O, Hoare J, et al. . A population-based, retrospective, cohort study of esophageal cancer missed at endoscopy. Endoscopy. 2014;46(7):553-560.
    1. Chadwick G, Groene O, Riley S, et al. . Gastric cancers missed during endoscopy in England. Clin Gastroenterol Hepatol. 2015;13(7):1264-1270.e1.
    1. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. . Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297.
    1. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME; Colorectal Cancer Study Group . Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004;351(26):2704-2714.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren